Value Proposition

  • Combining one of the world's most innovative drug discovery platforms with development of novel, best-in-class therapies.


Robust Clinical Development Programs

  • Lead development program BNC210 is a negative allosteric modulator alpha 7 nicotinic acetylcholine receptor.

  • Bionomics is progressing optimisation of its BNC210 tablets to use in its proposed second Phase 2 Post-Traumatic Stress Disorder (PTSD) trial by conducting testing in an animal study; completion projected in Q2 CY2020

  • An experimental Phase 2 clinical trial of BNC105, in combination with nivolumab, has commenced in patients with metastatic colorectal cancer, an Australasian Gastro-Intestinal Trials Group (AGITG) sponsored trial supportedby Bristol-Myers Squibb. 

Two Proprietary Technology Platforms 

  • Multicore®: suite of integrated pharmacophore modelling and synthetic methods for generating chemical diversity enabling rapid drug candidate identification.
  • ionX®:  integrated platform technologies that serve as the foundation of Bionomics' CNS drug discovery and development activities.

Strong Cash Position

  • Solid balance sheet.

  • Cash balance of AU$4.65M (as of 31 Mar 2020) to support clinical development programs.

  • Cash receipts for the period ending 31 March 2020 mainly related to receipts from customers totalling $0.997 million (31 December 2019: $1.55 million)

  • The Company completed the sale of its two wholly owned subsidiaries, Neurofit SAS ("Neurofit") and PC SAS ("Prestwick Chemical"), to Domain Therapeutics.  The sale price of EUR$1,790,028.97 was the final amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics' drug candidates and was assumed by Domain at close.

  • Market Cap: AU$28.8M (as at 31 March 2020).